Skip to main content
. 2022 Oct 18;14(20):5092. doi: 10.3390/cancers14205092

Figure 5.

Figure 5

scL-RB94 reduces immunosuppressive M2 macrophages. Athymic mice bearing either H358 or H292 tumors were treated with scL-RB94 (30 µg/injection/mouse, two injections over 3 days). Forty-eight hours later, harvested tumors were processed for flow cytometry or IHC analyses (N = 8). (A) Macrophages infiltrating H358 tumors were identified by flow cytometry using gates for M1 macrophages (CD11b+F4/80+CD86+) and M2 macrophages (CD11b+F4/80+CD206+) in CD45+ live cells. * p < 0.05, Student’s t test. (B) Representative staining for Arg-1, a common marker for M2 macrophages in H358 and H292 tumors. Arrows indicate Arg-1 positive cells.